| AMA | African Medicines Agency |
| AdV | Adenoviral |
| AVAREF | African Vaccine Regulatory Forum |
| AAV | Adeno-associated viral |
| CAR T cell | Chimeric antigen receptor T cell |
| CGD | Chronic granulomatous disease |
| CRISPR | Clustered regularly interspaced short palindromic repeats |
| EMA | European Medicine Agency |
| GMP | Good manufacturing practice |
| HICs | High-income countries |
| HSCs | Hematopoietic stem cells |
| HSPC | Hematopoietic stem and progenitor |
| LMICs | Low-and middle-income countries |
| ML3 | Maturity Level 3 |
| IV | Intravenous injection |
| LNPs | Lipid nanoparticles |
| LMICs | Low-and middle-income countries |
| SCD | Sickle cell disease |
| SMA | Spinal muscular atrophy |
| U.S. FDA | United States Food and Drug Administration |
| VLPs | Viral-like particles |
| WHO | World Health Organization |